Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
Survey: Lived experience & Quality of life
Call for participants - "Exploring the lived experiences and quality of life of individuals affected by CAH" If you're 18 years and over and living with CAH, tell us how CAH affects your life in an individual discussion held at a convenient time face-to-face or...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...